Sermorelin

Research OnlyModerate Evidence
Written by dr-sarah-chen|Reviewed by Healthier Rx Editorial Board|Updated 2026-04-01|4 min read
Quick Facts
TypeGH Secretagogue
FDA StatusResearch Only
Evidence LevelModerate Evidence
Typical Dose200-500mcg
FrequencyOnce nightly
Cycle Length3-6 months
Key GoalsAnti-Aging, Muscle Growth

How It Works

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of human growth hormone-releasing hormone (GHRH 1-29). This represents the shortest fully functional fragment of GHRH that retains complete biological activity. It was developed and previously FDA approved under the brand name Geref for diagnostic testing and treatment of GH deficiency in children, though approval was later withdrawn for commercial (not safety) reasons.

Sermorelin works by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating the natural synthesis and pulsatile release of endogenous growth hormone. This mechanism preserves the body's normal feedback regulation through the GH/IGF-1 axis, somatostatin inhibition, and the natural circadian rhythm of GH secretion — a critical advantage over direct exogenous GH administration.

When injected at bedtime, Sermorelin amplifies the nocturnal GH pulse — the largest natural GH release of the day. Over time, this leads to improved body composition, enhanced recovery, better sleep quality, and various anti-aging benefits associated with optimized GH levels.

Benefits

  • Stimulates natural, pulsatile GH release — preserves physiological regulation
  • Improved body composition — increased lean mass and reduced body fat over 3-6 months
  • Enhanced sleep quality — deeper sleep through amplified nocturnal GH pulse
  • Anti-aging effects — improved skin elasticity, energy, and vitality
  • Good safety profile — decades of clinical use and research
  • May restore pituitary sensitivity — potentially improving endogenous GH secretion long-term

Side Effects

  • Injection site reactions — redness, swelling, pain (most common)
  • Facial flushing — warmth immediately after injection, usually transient
  • Headache — occasional, typically resolves with continued use
  • Dizziness — rare
  • Difficulty swallowing — rare, reported in some clinical trials
  • Joint stiffness — typically mild, related to GH-mediated effects
  • Generally well-tolerated with a favorable safety profile over long treatment periods

Dosing Protocol

ParameterDetails
Standard Dose200-500mcg per injection
FrequencyOnce nightly, 30-60 minutes before bedtime
AdministrationSubcutaneous injection (abdomen or thigh)
Cycle Length3-6 months continuously
FastingEmpty stomach — no food for 2+ hours before injection
MonitoringCheck IGF-1 levels at baseline and every 3 months

What You Will Need

  • Sermorelin lyophilized vial (typically 9mg or 15mg)
  • Bacteriostatic water (30mL)
  • Insulin syringes (1mL, 29-31ga)
  • Alcohol swabs
  • Sharps container

Frequently Asked Questions

References

  1. Growth hormone-releasing hormone therapy in adults with growth hormone deficiencyEndocrine (2017). PMID: 28185174

    Review of GHRH therapy including Sermorelin for adult GH deficiency, demonstrating effectiveness in restoring physiological GH secretion.

  2. Sermorelin: a review of its use in the management of growth hormone deficiency in childrenClinical Drug Investigation (1998). PMID: 18370949

    Review of Sermorelin's clinical profile including efficacy and safety data from pediatric GH deficiency trials.

  3. Effects of GHRH on body composition and metabolic parameters in adultsGrowth Hormone & IGF Research (2005). PMID: 16098780

    Study demonstrating GHRH therapy improves body composition with increased lean mass and reduced adiposity in older adults.

Protocols Featuring Sermorelin

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new treatment or protocol. Read our full medical disclaimer.